Biotech entity

Evolus, Inc.

Company EOLS

Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention David Moatazedi, the most common co-covered peer. Evolus, Inc. appears in 1 tracked Biotech story from March 5, 2026. The tracked stories average 4 original sources each.

Last mentioned: Mar 5, 2026

RSS updates
Share

Entity pulse

Recent coverage · Evolus, Inc.

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Evolus, Inc.

Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention David Moatazedi, the most common co-covered peer. Evolus, Inc. appears in 1 tracked Biotech story from March 5, 2026. The tracked stories average 4 original sources each.

Stories tracked
1
Sources per story
4

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 13 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Evolus, Inc.. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Anticipated FDA Approval

    Expected regulatory clearance for the first Evolysse filler products.

  2. Commercial Launch

    Planned U.S. launch of the Evolysse filler portfolio to aesthetic injectors.

  3. Q4 Earnings

    Company reports record revenue and market share for Jeuveau.

  4. Filler Partnership

    Evolus expands partnership with Symatese for the Evolysse dermal filler line.

Stories mentioning Evolus, Inc. 1

Pharma Neutral

Evolus Q4 2025: Jeuveau Market Share Surges as Dermal Filler Launch Approaches

Evolus, Inc. reported strong Q4 2025 results, driven by the continued market share expansion of its flagship neurotoxin, Jeuveau, and progress in its international rollout. The company remains on track to transform into a multi-product aesthetics platform with the anticipated 2026 launch of its Evolysse dermal filler line.

4 sources

Evolus, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.